WARNING LETTER
Laser Dental Innovations
MARCS-CMS 546341 —
February 27, 2018
Recipient:
Recipient Name
Howard A. Feinberg
Laser Dental Innovations
1219 Quail Creek Circle
San Jose
,
CA
95120
United States
Issuing Office:
Los Angeles District Office
United States
Office of Medical Device and Radiological Health Operations
Division 3West
19701 Fairchild
Irvine, CA 92612
WARNING LETTER
CMS # 546341
UNITED PARCEL SERVICE
OVERNIGHT DELIVERY
February 27, 2018
Howard A. Feinberg, President
Laser Dental Innovations
1219 Quail Creek Circle
San Jose, California 95120
Dear Mr. Feinberg:
The United States Food and Drug Administration (FDA) conducted an inspection of your firm’s medical device operations at 1219 Quail Creek Circle, San Jose, California from December 4-14, 2017. During the inspection, an FDA investigator determined that your firm is a manufacturer of the dental handpiece and laser fiber optic surgical devices. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.
This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received your response dated December 22, 2017, concerning our investigator’s observations noted on the Form FDA 483, List of Inspectional Observations (FDA 483) that was issued on December 14, 2017. We address the response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:
1.    Your firm failed to establish procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a).
Your firm’s “Corrective and Preventive Action (CAPA)”, document SOP028A dated December 20, 2006 states your firm will document your CAPA activities on a Corrective Action Form (FRM 017) and will include the details of the investigation, a root cause analysis to identify cause, corrective actions taken, list of impacted records, and an appropriate method for verifying effectiveness of the corrective actions.
a.  Your firm did not document CAPAs
(b)(4)
or
(b)(4)
on your Corrective Action Form. Additionally, the records documenting these CAPAs did not include a root cause analysis or investigation details, as required by your CAPA procedure.
b.  Your Corrective Action Forms for CAPAs
(b)(4)
and
(b)(4)
do not include the complete specific corrective actions or documents associated with the corrections and do not include methods for verifying the effectiveness of those corrective actions.
We have reviewed your response dated December 22, 2017 and determined it is inadequate. Your response did not include actions taken to remedy CAPAs
(b)(4).
Additionally, your response states CAPA SOP 028 will be updated to "best reflect the needs of the business"; however, your response does not address the specific changes that will be implemented to ensure compliance with the requirements of 21 CFR 820.100.
2.    Your firm failed to maintain complaint files and establish procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a).
Your firm's procedure entitled "Customer Communication & Complaint Handling", SOP019B dated January 28, 2008, identifies your fnm's procedures for complaint handling. It states in section 6.1 "all communications dealing with complaints or problems will be documented and investigated." You stated during the inspection your CAPA
(b)(4)
was opened in response to multiple complaints associated with broken or improperly functioning collets in the LiteSaber Handpieces. Your fnm did not have any record identifying the information required to be maintained by 21 CFR 820.198.
We have reviewed your response and determined it is inadequate. Although your response states you will begin to follow your "Customer Communication & Complaint Handling" procedure, your response does not include any retrospective evaluation to determine additional complaints received which have not been documented.
3.    Your firm failed to establish procedures to control the design of the device in order to ensure that specified design requirements are met, as required by 21 CFR 820.30. For example,
a.  Your firm's "Risk Management" procedure, SOP008A, dated Jul 19, 2007, states conduct a risk analysis which includes
(b)(4)
. However, your fnm did not conduct these activities for your LiteSaber 10 mm Handpiece nor your StarLite Fiber Optic devices.
b.  Your firm’s design history files for your LiteSaber 10 mm Handpiece and your StarLite Fiber Optic devices do not include records for design validation or design verification and you stated these records did not exist.
We have reviewed your response and determined it is inadequate. Your response states your firm will apply your design control activities for new designs and design changes. Although your design control procedures were not in place when the original design activities were conducted, your firm is still required to follow the requirements of 21 CFR 820.30. Where possible, your firm should retrospectively conduct and document these activities.
4.    Your firm failure to establish procedures to ensure that all purchased or otherwise received product and services conform to specified requirements, as required by 21 CFR 820.50.
Your firm’s “Purchasing, Supplier Quality, Receiving Inspection”, procedure SOP023A dated December 20, 2006, states in section 2.1 “The requirements for purchasing controls for Laser Dental Innovation’s Design and/or Manufacturing (D&M) Contractors are defined in their Supplier Contracts”. However, your firm has not established any supplier contracts for your contract suppliers. Further, your firm has not evaluated your suppliers to ensure they are able to meet specified requirements.
We have reviewed your response and determined it is inadequate. Your response states you will generate supplier profiles and contracts for your
(b)(4)
critical suppliers; however, you did not define how your firm determines a supplier to be critical. Additionally, your response does not address how your firm will apply purchasing controls to all suppliers.
5.    Your firm failed to establish procedures to ensure that device history records (DHR) for each batch, lot, or unit are maintained to demonstrate that the device is manufactured in accordance with the device master record (DMR), as required by 21 CFR 820.184.
a.  Your firm’s DHR for lot 700 of your LiteSaber Handpiece does not include the quantity of products released for distribution, the acceptance records showing the product was made in compliance with the DMR, or the primary identification label.
b.  Your firm’s DHR for lot 17-03-7105 of your Starlite Fiber devices does not include the quantity of products released for distribution, the acceptance records showing the product was made in compliance with the DMR, or the primary identification label.
c.  Your firm’s DHR for lot 17-03-7106 of your Starlite Fiber devices does not include the quantity of products released for distribution, the acceptance records showing the product was made in compliance with the DMR, or the primary identification label.
We have reviewed your response and determined the response is inadequate. Although your response states you will implement your DHR procedure SOP 018; your response does not include any retrospective review of your manufactured product to determine if additional lots’ DHRs were deficient. Additionally, your response does not address how your firm will remedy the deficient DHRs identified on the FDA 483.
6.    Your firm failed to establish and maintain procedures for quality audits and conduct such audits to assure that the quality system is in compliance with the established quality system requirements and to determine the effectiveness of the quality system, as required by 21 CFR 820.22.
Your firm’s “Internal Quality System Audits” procedure SOP027B, dated August 7, 2007 states your firm will conduct internal quality audits once a year at a minimum. Your firm has not conducted an internal audit since 2011.
We have reviewed your response and determined it is inadequate. Your firm’s response states your firm intends to modify your procedure to require external quality audits to be conducted every
(b)(4)
. Your response is unclear on if this external quality audit is intended to be in addition to or in lieu of your annual internal audit. Additionally, your response does not address how your firm will ensure your annual internal audit will be conducted to ensure that individuals conducting the audit are not directly responsible for the areas being audited.
Your firm should take prompt action to correct the violations addressed in this letter. Failure to promptly correct these violations may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties. Also, federal agencies may be advised of the issuance of Warning Letters about devices so that they may take this information into account when considering the award of contracts. Additionally, premarket approval applications for Class III devices to which the Quality System regulation violations are reasonably related will not be approved until the violations have been corrected. Requests for Certificates to Foreign Governments will not be granted until the violations related to the subject devices have been corrected.
Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to correct the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and/or corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and/or corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and/or corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address all violations included in this Warning Letter.
Your firm’s response should be sent via e-mail to: US Food and Drug Administration, Division 3/West, Office of Medical Device and Radiological Health Operations at
ORADevices3FirmResponse@fda.hhs.gov
. Please identify your response with FEI 3012547534. If you have any questions about the contents of this letter, please contact Compliance Officer Jeff R. Wooley at 214-253-5251, or via e-mail at
Jeffrey.wooley@fda.hhs.gov
Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of the violations, and take prompt actions to correct the violations and bring the products into compliance.
Sincerely,
/S/
Shari J. Shambaugh
Program Division Director
Office of Medical Device and Radiological Health
Division 3 West
Content current as of:
03/13/2018